纳武利尤单抗对比多西他赛对晚期鳞状非小细胞肺癌患者健康相关生活质量及症状的影响:CheckMate 017研究结果
CheckMate 017 III期研究显示,经治晚期鳞状非小细胞肺癌患者中,纳武利尤单抗对比多西他赛延长总生存。本研究评估生活质量与症状,患者序列填写LCSS和EQ-5D问卷。第12周ASBI临床有意义改善比例两组相似,但第16至54周纳武利尤单抗组ASBI评分较基线显著改善,且至首次生活质量恶化时间更长。结论:纳武利尤单抗二线治疗减轻症状负担并改善健康状况。
要点
- 第12周ASBI临床有意义改善比例纳武利尤单抗20.0% vs 多西他赛21.9%。
- 第16至54周纳武利尤单抗组ASBI评分较基线显著改善,第42至84周达临床有意义改善。
- 多西他赛组ASBI无显著变化,第36周出现临床有意义恶化。
核心结论
- 纳武利尤单抗作为二线治疗减轻晚期鳞状非小细胞肺癌患者症状负担并改善健康状况,优于多西他赛。
研究设计与样本
- III期CheckMate 017研究的生活质量与症状分析,患者序列完成LCSS和EQ-5D问卷。
- 分析LCSS平均症状负担指数(ASBI,范围0-100)、LCSS三项全局指数、EQ-5D效用指数和EQ-5D视觉模拟量表评分。
- 第12周ASBI评分临床有意义改善(≥10分下降)比例为次要终点。
- 采用混合效应模型重复测量分析生活质量自基线变化及至生活质量恶化时间分析。
主要发现
- 基线平均LCSS ASBI评分纳武利尤单抗组29.6±16.4,多西他赛组29.6±14.7。
- 第12周ASBI临床有意义改善比例纳武利尤单抗20.0%(95%CI 13.6-27.7),多西他赛21.9%(95%CI 15.3-29.8)。
- 第16至54周纳武利尤单抗组ASBI评分较基线显著改善,第42至84周达临床有意义改善。
- 多西他赛组ASBI评分较基线无显著变化,第36周出现临床有意义恶化。
- 其他指标支持纳武利尤单抗对比多西他赛的生活质量改善,且至首次生活质量恶化时间更长。
关键数值与推荐
- ASBI评分范围0-100,临床有意义改善定义为≥10分下降。
- 第12周ASBI临床有意义改善比例纳武利尤单抗20.0%(95%CI 13.6-27.7),多西他赛21.9%(95%CI 15.3-29.8)。
- 基线平均LCSS ASBI评分纳武利尤单抗29.6±16.4,多西他赛29.6±14.7。
临床怎么用
- 对于经治晚期鳞状非小细胞肺癌,纳武利尤单抗二线治疗可减轻症状负担并改善生活质量。
- 临床决策时可参考纳武利尤单抗在生活质量方面的获益。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: In the phase III CheckMate 017 study, nivolumab prolonged overall survival versus docetaxel in previously treated patients with advanced squamous NSCLC. Study objectives included health-related quality of life (HRQoL) and symptom assessments. METHODS: Patients serially completed the Lung Cancer Symptom Scale (LCSS) and European Quality of Life Five Dimensions (EQ-5D) questionnaires. The LCSS average symptom burden index (ASBI) (mean score for six lung cancer-specific symptoms; range 0-100), LCSS three-item global index, EQ-5D utility index, and EQ-5D visual analog scale scores were analyzed. The proportion of patients exhibiting clinically meaningful improvement (a ≥10-point decrease) in ASBI scores by week 12 was a secondary end point. Mixed-effect model repeated measures analysis of HRQoL changes from baseline and analyses of time to HRQoL deterioration were conducted. RESULTS: Baseline mean plus or minus SD LCSS ASBI scores were similar in the nivolumab (29.6 ± 16.4) and docetaxel (29.6 ± 14.7) groups. By week 12, the proportions of patients (95% confidence interval) with clinically meaningful improvement in ASBI scores were 20.0% (13.6-27.7) with nivolumab and 21.9% (15.3-29.8) with docetaxel. At weeks 16 to 54, significant improvements in ASBI scores from baseline were seen with nivolumab; clinically meaningful improvements were observed at weeks 42 to 84. No significant changes in ASBI scores from baseline were observed with docetaxel; at week 36, a clinically meaningful deterioration was seen. Improvements in HRQoL with nivolumab versus with docetaxel were supported by other measures, and time to first HRQoL deterioration was longer. CONCLUSION: Nivolumab alleviates symptom burden and improves health status versus docetaxel as second-line squamous NSCLC treatment.
引用
- Reck M, Taylor F, Penrod JR, et al. Impact of Nivolumab versus Docetaxel on Health-Related Quality of Life and Symptoms in Patients with Advanced Squamous Non-Small Cell Lung Cancer: Results from the CheckMate 017 Study. J Thorac Oncol. 2017. PMID: 29129758. doi:10.1016/j.jtho.2017.10.029
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。